Literature DB >> 17274795

Outcome of allogeneic vascularized knee transplants.

Michael Diefenbeck1, Frithjof Wagner, Martin H Kirschner, Andreas Nerlich, Thomas Mückley, Gunther O Hofmann.   

Abstract

Transplantation of vascularized knee joints is a novel approach in Composite Tissue Allotransplantation (CTA). In 1996 our group started a clinical knee transplantation project and six transplantations have been performed since. Key problems identified early were the monitoring of acute rejection and choice of an immunosuppressive regime. One graft was lost due to postoperative infection and one due to of noncompliance where the patient discontinued the immunosuppressant regime. In three cases late rejection lead to necrosis and graft dysfunction after 15, 16 and 24 months, respectively. Exit-strategies were arthrodesis in one patient and Above Knee Amputation in two cases. With retrospective analysis after initial five cases the treatment protocol was improved. The immunosuppressive drug regime was altered, femoral diaphysis and knee joint grafting was combined and a vascularized block of donor skin and subcutaneous tissue was harvested with the graft (sentinel skin graft). The sentinel skin graft enabled us to monitor acute rejection by clinical and histological examination and avoid late rejection by rapid treatment with high dose steroids. In summary, over a four-year period, one of six allogeneic vascularized knee transplants has survived, one was lost from a surgical site infection, one by noncompliance and three by late rejection. Analysis of our data leads us to suggest that knee transplantation should be limited to a combined injury consisting of extensive loss of cartilage and bone, deficient extensor mechanism and soft tissue and skin defects without any signs of infection. Transplantation should only be taken into consideration as last option before Above Knee Amputation in an otherwise healthy patient under 35 years of age.

Entities:  

Mesh:

Year:  2007        PMID: 17274795     DOI: 10.1111/j.1432-2277.2007.00453.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

1.  Knee joint transplantation combined with surgical angiogenesis in rabbits--a new experimental model.

Authors:  Thomas Kremer; Guilherme Giusti; Patricia F Friedrich; Wouter Willems; Allen T Bishop; Goetz A Giessler
Journal:  Microsurgery       Date:  2011-11-24       Impact factor: 2.425

2.  Living bone allotransplants survive by surgical angiogenesis alone: development of a novel method of composite tissue allotransplantation.

Authors:  Mikko Larsen; Michael Pelzer; Patricia F Friedrich; Christina M Wood; Allen T Bishop
Journal:  J Bone Joint Surg Am       Date:  2011-02-02       Impact factor: 5.284

3.  A modified vascularized whole knee joint allotransplantation model in the rat.

Authors:  Mikko Larsen; Patricia F Friedrich; Allen T Bishop
Journal:  Microsurgery       Date:  2010-10       Impact factor: 2.425

4.  Experimental remodellation of extracorporeal irradiated autogenous and allogenic patellar grafts.

Authors:  Elhan Gasimov; Dundar Sabah; Ozlem Yilmaz; Burcin Kececi; Gulperi Oktem
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-01-29

Review 5.  [Healing of free vascularized bone allotransplants: optimizing by short-term immunosuppression and host-derived neovascularization].

Authors:  G A Giessler; P F Friedrich; R H Shin; A T Bishop
Journal:  Unfallchirurg       Date:  2009-05       Impact factor: 1.000

Review 6.  Science of composite tissue allotransplantation.

Authors:  Bruce Swearingen; Kadiyala Ravindra; Hong Xu; Shengli Wu; Warren C Breidenbach; Suzanne T Ildstad
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

7.  A Flow Dynamic Rationale for Accelerated Vascularized Composite Allotransplant Rejection.

Authors:  Nicholas L Robbins; Matthew J Wordsworth; Bijaya K Parida; Bruce Kaplan; Vijay S Gorantla; Col Erik K Weitzel; Warren C Breidenbach
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.